

# Contents

### Highlights of This Issue 6603

#### SPECIAL FEATURES

##### CCR Translations

- 6605 | **Is It Downhill from Here? Eliminating Leukemic Stem Cells and Curing Chronic Myeloid Leukemia**  
Catherine C. Smith and Neil P. Shah  
*See article p. 6812*

##### CCR Perspectives in Drug Approval

- 6608 | **The European Medicines Agency Review of Pazopanib for the Treatment of Advanced Renal Cell Carcinoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use**  
Maria Nieto, Jeanett Borregaard, Jens Ersbøll, George J.A. ten Bosch, Barbara van Zwieten-Boot, Eric Abadie, Jan H.M. Schellens, and Francesco Pignatti

##### CCR Drug Updates

- 6615 | **Eribulin Mesylate**  
Sarika Jain and Linda T. Vahdat

##### Molecular Pathways

- 6623 | **MALT1 Protease: A New Therapeutic Target in B Lymphoma and Beyond?**  
Linda M. McAllister-Lucas, Mathijs Baens, and Peter C. Lucas

##### Special Reports

- 6632 | **Achieving the Goals of Effective, Safe, and Individualized Cancer Care**  
Samantha A. Roberts, Erin K. Karnes, Jeffrey D. Allen, Joshua S. Benner, Ellen V. Sigal, and Mark McClellan
- 6634 | **Adaptive Clinical Trial Designs for Simultaneous Testing of Matched Diagnostics and Therapeutics**  
Howard I. Scher, Shelley Fuld Nasso, Eric H. Rubin, and Richard Simon

- 6641 | **Identification and Elucidation of the Biology of Adverse Events: The Challenges of Safety Assessment and Translational Medicine**  
Kenneth W. Turteltaub, Myrtle A. Davis, Leigh Ann Burns-Naas, Michael P. Lawton, Adam M. Clark, and Jack A. Reynolds
- 6646 | **Integrating Pain Metrics into Oncology Clinical Trials**  
Charles S. Cleeland, Ann O'Mara, Martin Zagari, and Carole Baas
- 6651 | **Using Patient-Initiated Study Participation in the Development of Evidence for Personalized Cancer Therapy**  
Laurie Fenton Ambrose, Jamie Freedman, Kenneth Buetow, Stephen Friend, and Richard L. Schilsky

#### HUMAN CANCER BIOLOGY

- 6658 | **Disruptive TP53 Mutation Is Associated with Aggressive Disease Characteristics in an Orthotopic Murine Model of Oral Tongue Cancer**  
Daisuke Sano, Tong-Xin Xie, Thomas J. Ow, Mei Zhao, Curtis R. Pickering, Ge Zhou, Vlad C. Sandulache, David A. Wheeler, Richard A. Gibbs, Carlos Caulin, and Jeffrey N. Myers
- 6671 | **Merkel Cell Polyomavirus-Specific CD8<sup>+</sup> and CD4<sup>+</sup> T-cell Responses Identified in Merkel Cell Carcinomas and Blood**  
Jayasri G. Iyer, Olga K. Afanasiev, Christopher McClurkan, Kelly Paulson, Kotaro Nagase, Lichen Jing, Joshua O. Marshak, Lichun Dong, Joseph Carter, Ivy Lai, Erik Farrar, David Byrd, Denise Galloway, Cassian Yee, David M. Koelle, and Paul Nghiem
- 6681 | **Expression of NLRP3 Orphan Receptor Gene Is Negatively Regulated by MYCN and Miz-1, and Its Downregulation Is Associated with Unfavorable Outcome in Neuroblastoma**  
Jesmin Akter, Atsushi Takatori, Md. Shamim Hossain, Toshinori Ozaki, Atsuko Nakazawa, Miki Ohira, Yusuke Suenaga, and Akira Nakagawara

6693 **Insulin-like Growth Factor–Binding Protein-7 Functions as a Potential Tumor Suppressor in Hepatocellular Carcinoma**  
Dong Chen, Byoung Kwon Yoo, Prasanna Kumar Santhekadur, Rachel Gredler, Sujit K. Bhutia, Swadesh K. Das, Christine Fuller, Zao-zhong Su, Paul B. Fisher, and Devanand Sarkar

6766 **The Phosphatase Inhibitor Menadione (Vitamin K3) Protects Cells from EGFR Inhibition by Erlotinib and Cetuximab**  
Roman Perez-Soler, Yiyu Zou, Tianhong Li, and Yi He Ling

## CANCER THERAPY: PRECLINICAL

6702 **rILYd4, a Human CD59 Inhibitor, Enhances Complement-Dependent Cytotoxicity of Ofatumumab against Rituximab-Resistant B-cell Lymphoma Cells and Chronic Lymphocytic Leukemia**  
Xiaowen Ge, Lin Wu, Weiguo Hu, Stacey Fernandes, Chun Wang, Xu Li, Jennifer R. Brown, and Xuebin Qin

6712 **Species D Adenoviruses as Oncolytics against B-cell Cancers**  
Christopher Y. Chen, Julien S. Senac, Eric A. Weaver, Shannon M. May, Diane F. Jelinek, Philip Greipp, Thomas Witzig, and Michael A. Barry

6723 **Gene Set Enrichment Analysis Unveils the Mechanism for the Phosphodiesterase 4B Control of Glucocorticoid Response in B-cell Lymphoma**  
Sang-Woo Kim, Deepak Rai, and Ricardo C.T. Aguiar

6733 **A Novel Anti-Human HB-EGF Monoclonal Antibody with Multiple Antitumor Mechanisms against Ovarian Cancer Cells**  
Shingo Miyamoto, Ryo Iwamoto, Akiko Furuya, Kumiko Takahashi, Yuka Sasaki, Hiroshi Ando, Fusanori Yotsumoto, Tomoko Yoneda, Miki Hamaoka, Hiroshi Yagi, Takuya Murakami, Sayaka Hori, Kenya Shitara, and Eisuke Mekada

6742 **TLR2 Agonist PSK Activates Human NK Cells and Enhances the Antitumor Effect of HER2-Targeted Monoclonal Antibody Therapy**  
Hailing Lu, Yi Yang, Ekram Gad, Carol Inatsuka, Cynthia A. Wenner, Mary L. Disis, and Leanna J. Standish

6754 **TGF $\beta$ 1 Inhibition Increases the Radiosensitivity of Breast Cancer Cells *In Vitro* and Promotes Tumor Control by Radiation *In Vivo***  
Fanny Bouquet, Anupama Pal, Karsten A. Pilones, Sandra Demaria, Byron Hann, Rosemary J. Akhurst, Jim S. Babb, Scott M. Lonning, J. Keith DeWyngaert, Silvia C. Formenti, and Mary Helen Barcellos-Hoff

## IMAGING, DIAGNOSIS, PROGNOSIS

6778 **The Prognostic Significance of Various 13q14 Deletions in Chronic Lymphocytic Leukemia**  
Peter Ouillette, Roxane Collins, Sajid Shakhan, Jinghui Li, Cheng Li, Kerby Shedden, and Sami N. Malek

6791 **Expression of FoxM1 Is Required for the Proliferation of Medulloblastoma Cells and Indicates Worse Survival of Patients**  
Markus Priller, Julia Pöschl, Leticia Abrão, André O. von Bueren, Yoon-Jae Cho, Stefan Rutkowski, Hans A. Kretzschmar, and Ulrich Schüller

6802 **A 5-MicroRNA Signature for Lung Squamous Cell Carcinoma Diagnosis and hsa-miR-31 for Prognosis**  
Xiaogang Tan, Wenyan Qin, Liang Zhang, Jie Hang, Baozhong Li, Cuiyan Zhang, Junting Wan, Fang Zhou, Kang Shao, Yimin Sun, Jianping Wu, Xun Zhang, Bin Qiu, Ning Li, Susheng Shi, Xiaoli Feng, Shouhua Zhao, Zhen Wang, Xiaohong Zhao, Zhaoli Chen, Keith Mitchelson, Jing Cheng, Yong Guo, and Jie He

## CANCER THERAPY: CLINICAL

6812 **BCR–ABL Transcript Dynamics Support the Hypothesis That Leukemic Stem Cells Are Reduced during Imatinib Treatment**  
Andrew M. Stein, Dean Bottino, Vijay Modur, Susan Branford, Jaspal Kaeda, John M. Goldman, Timothy P. Hughes, Jerald P. Radich, and Andreas Hochhaus  
*See commentary p. 6605*

6822 **Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor–Positive Locally Advanced or Metastatic Breast Cancer**  
Nuhad K. Ibrahim, Kemal O. Yariz, Ihor Bondarenko, Alexei Manikhas, Vladimir Semiglazov, Anna Alyasova, Volodymyr Komisarenko, Yaroslav Shparyk, James Lee Murray, David Jones, Shai Senderovich, Albert Chau, Fredrik Erlandsson, Gary Acton, and Mark Pegram

6831 **A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas**

Arun Rajan, Ronan J. Kelly, Jane B. Trepel, Yeong Sang Kim, Sylvia V. Alarcon, Shivaani Kummur, Martin Gutierrez, Sonja Crandon, Wadih M. Zein, Lokesh Jain, Baskar Mannargudi, William D. Figg, Brett E. Houk, Michael Shnaidman, Nicoletta Brega, and Giuseppe Giaccone

6840 **A Phase I Trial of Liposomal Doxorubicin, Bevacizumab, and Temozolimum in Patients with Advanced Gynecologic and Breast Malignancies**

John W. Moroney, Matthew P. Schlumbrecht, Thorunn Helgason, Robert L. Coleman, Stacy Moulder, Aung Naing, Diane C. Bodurka, Filip Janku, David S. Hong, and Razelle Kurzrock

6847 **Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial**

Paal Fr. Brunsvig, Jon Amund Kyte, Christian Kersten, Stein Sundstrøm, Mona Møller, Marta Nyakas, Gaute L. Hansen, Gustav Gaudernack, and Steinar Aamdal

6858 **Phase II Study of Oral Capsular 4-Hydroxyphenylretinamide (4-HPR/Fenretinide) in Pediatric Patients with Refractory or Recurrent Neuroblastoma: A Report from the Children's Oncology Group**

Judith G. Villablanca, Wendy B. London, Arlene Naranjo, Patrick McGrady, Matthew M. Ames, Joel M. Reid, Renee M. McGovern, Sarah A. Buhrow, Hollie Jackson, Enno Stranzinger, Brenda J. Kitchen, Paul M. Sondel, Marguerite T. Parisi, Barry Shulkin, Gregory A. Yanik, Susan L. Cohn, and C. Patrick Reynolds

6867 **Population Pharmacokinetics of Busulfan in Children: Increased Evidence for Body Surface Area and Allometric Body Weight Dosing of Busulfan in Children**

Mirjam N. Trame, Martin Bergstrand, Mats O. Karlsson, Joachim Boos, and Georg Hempel

6878 **Phase I Trial of Adoptive Cell Transfer with Mixed-Profile Type-I/Type-II Allogeneic T Cells for Metastatic Breast Cancer**

Nancy M. Hardy, Miriam E. Mossoba, Seth M. Steinberg, Vicki Fellowes, Xiao-Yi Yan, Frances T. Hakim, Rebecca R. Babb, Daniele Avila, Juan Gea-Banacloche, Claude Sportès, Bruce L. Levine, Carl H. June, Hahn M. Khuu, Ashley E. Carpenter, Michael C. Krumlauf, Andrew J. Dwyer, Ronald E. Gress, Daniel H. Fowler, and

Michael R. Bishop

6888 **Phase I Safety and Pharmacokinetic Study of Bavixumab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients with Advanced Solid Tumors**

David E. Gerber, Alison T. Stopeck, Lucas Wong, Lee S. Rosen, Philip E. Thorpe, Joseph S. Shan, and Nuhad K. Ibrahim

6897 **A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor-Positive Breast Cancer**

Erica L. Mayer, Jean-Francois Baurain, Joseph Sparano, Lewis Strauss, Mario Campone, Pierre Fumoleau, Hope Rugo, Ahmad Awada, Oumar Sy, and Antonio Llombart-Cussac

6905 **Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study**

Richard S. Finn, Carmelo Bengala, Nuhad Ibrahim, Henri Roché, Joseph Sparano, Lewis C. Strauss, Justin Fairchild, Oumar Sy, and Lori J. Goldstein

6914 **Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and Pharmacodynamics**

Thomas Yau, Pei-Jer Chen, Pierre Chan, C. Martin Curtis, Philip S. Murphy, A. Benjamin Suttle, Jennifer Gauvin, Jeffrey P. Hodge, Mohammed M. Dar, and Ronnie T. Poon

## PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

6924 **iASPP and Chemoresistance in Ovarian Cancers: Effects on Paclitaxel-Mediated Mitotic Catastrophe**

LiLi Jiang, Michelle K.Y. Siu, Oscar G.W. Wong, Kai-Fai Tam, Xin Lu, Eric W-F. Lam, Hextan Y. S. Ngan, Xiao-Feng Le, Esther S.Y. Wong, Lara J. Monteiro, Hoi-Yan Chan, and Annie N.Y. Cheung

6934 **Common Cancer Stem Cell Gene Variants Predict Colon Cancer Recurrence**

Armin Gerger, Wu Zhang, Dongyun Yang, Pierre Bohanes, Yan Ning, Thomas Winder, Melissa J. LaBonte, Peter M. Wilson, Leonor Benhaim, David Paez, Rita El-Khoueiry, Anthony El-Khoueiry, Michael Kahn, and Heinz-Josef Lenz

---

## CORRECTION

6944

**Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: Results from the NSABP P1 and P2 Clinical Trials**

Matthew P. Goetz, Daniel J. Schaid, D. Lawrence Wickerham, Stephanie Safgren, Taisei Mushiroda, Michiaki Kubo, Anthony Batzler, Joseph P. Costantino, Victor G. Vogel, Soonmyung Paik, Erin E. Carlson, David A. Flockhart, Norman Wolmark, Yusuke Nakamura, Richard M. Weinshilboum, James N. Ingle, and Matthew M. Ames


6952

**Correction: Ribavirin Treatment Effects on Breast Cancers Overexpressing eIF4E, a Biomarker with Prognostic Specificity for Luminal B-Type Breast Cancer**

---

## ABOUT THE COVER

The image displays a section of a human medulloblastoma sample that has been stained with antibodies against the transcription factor FoxM1 (green) and the proliferation marker Ki67 (red). Tumor cell nuclei are visualized by DAPI. Expression of FoxM1 is not restricted to proliferating cells, as revealed by nuclei that are labeled green but lack red staining. For details, see the article by Priller and colleagues on page 6791 of this issue.



# Clinical Cancer Research

**17 (21)**

*Clin Cancer Res* 2011;17:6603-6952.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/17/21>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/17/21>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.